Akebia Therapeutics Q2 revenue smashes expectations

Akebia Therapeutics

07/08/2025 12:35

Overview

Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations

Net income for Q2 2025 beats estimates, reaching $0.2 mln

Company expands Vafseo prescribing access through dialysis partnerships

Result Drivers

VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions

DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3

REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$62.47 mln
$47.20 mln (5 Analysts)
Q2 EPS
-$0.02 (4 Analysts)
Q2 Net Income
Beat
$247,000
-$4.67 mln (4 Analysts)
Q2 Operating Income
Beat
$14.09 mln
$2.03 mln (3 Analysts)
Q2 Basic EPS
Q2 Operating Expenses
$38.46 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79

Press Release: ID:nGNX86RVjh

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)